Last reviewed · How we verify
Azacitidine for Intravenous Infusion
At a glance
| Generic name | Azacitidine for Intravenous Infusion |
|---|---|
| Also known as | Azacitidine |
| Sponsor | Aptose Biosciences Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Genotype-guided Targeted Agents Plus EZH2i for Primary Refractory PTCL (PHASE1, PHASE2)
- Maintenance Therapy of Hypomethylating Agent (HMA) in Favorable Risk Acute Myeloid Leukemia (AML) Patients (PHASE2)
- A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies (PHASE2)
- Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML (PHASE1)
- Pacritinib With Aza for Upfront Myelodysplastic Syndrome (PHASE1, PHASE2)
- A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML (PHASE1)
- Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia (PHASE2)
- A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Azacitidine for Intravenous Infusion CI brief — competitive landscape report
- Azacitidine for Intravenous Infusion updates RSS · CI watch RSS
- Aptose Biosciences Inc. portfolio CI